These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of the behavioral and neurochemical effects of 5,7-DHT, MDMA and D,L-fenfluramine. Lorens SA; Hata N; Cabrera T; Hamilton ME NIDA Res Monogr; 1989; 95():347. PubMed ID: 2577039 [No Abstract] [Full Text] [Related]
6. Regional distribution to recovery of 5-HT levels after administration of "atrophins" MDMA and D,L-fenfluramine. Stereospecificity and comparison with 5,7-dihydroxytryptamine. Lehmann J; DeSouza EB; Culp S; Zaczek R Ann N Y Acad Sci; 1992 May; 648():291-5. PubMed ID: 1379013 [No Abstract] [Full Text] [Related]
7. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Berger UV; Gu XF; Azmitia EC Eur J Pharmacol; 1992 May; 215(2-3):153-60. PubMed ID: 1356787 [TBL] [Abstract][Full Text] [Related]
8. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644 [TBL] [Abstract][Full Text] [Related]
10. Acute and subchronic effects of methylenedioxymethamphetamine [(+/-)MDMA] on locomotion and serotonin syndrome behavior in the rat. Spanos LJ; Yamamoto BK Pharmacol Biochem Behav; 1989 Apr; 32(4):835-40. PubMed ID: 2572003 [TBL] [Abstract][Full Text] [Related]
12. Responses to i.v. L-tryptophan in MDMA users. Price LH; Ricaurte GA; Krystal JH; Heninger GR NIDA Res Monogr; 1989; 95():421-2. PubMed ID: 2577044 [No Abstract] [Full Text] [Related]
13. Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice. Achat-Mendes C; Ali SF; Itzhak Y Neuropsychopharmacology; 2005 Jun; 30(6):1128-37. PubMed ID: 15688084 [TBL] [Abstract][Full Text] [Related]
14. Reduction of in vivo binding of [3H]paroxetine in mouse brain by 3,4-methylenedioxymethamphetamine. Hashimoto K; Goromaru T Neuropharmacology; 1990 Jul; 29(7):633-9. PubMed ID: 1696701 [TBL] [Abstract][Full Text] [Related]
15. Ecstasy: towards an understanding of the biochemical basis of the actions of MDMA. Rattray M Essays Biochem; 1991; 26():77-87. PubMed ID: 1685707 [No Abstract] [Full Text] [Related]
16. L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats. Schmidt CJ; Black CK; Taylor VL Eur J Pharmacol; 1991 Oct; 203(1):41-9. PubMed ID: 1686766 [TBL] [Abstract][Full Text] [Related]
17. Serotonergic modulation of rat pup ultrasonic vocal development: studies with 3,4-methylenedioxymethamphetamine. Winslow JT; Insel TR J Pharmacol Exp Ther; 1990 Jul; 254(1):212-20. PubMed ID: 1973197 [TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of MDMA-like substances. Nichols DE; Oberlender R NIDA Res Monogr; 1989; 94():1-29. PubMed ID: 2575223 [No Abstract] [Full Text] [Related]
19. Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity. Grob C; Bravo G; Walsh R Arch Gen Psychiatry; 1990 Mar; 47(3):288-9. PubMed ID: 1968330 [No Abstract] [Full Text] [Related]
20. Designer drug confusion: a focus on MDMA. Beck J; Morgan PA J Drug Educ; 1986; 16(3):287-302. PubMed ID: 2877058 [No Abstract] [Full Text] [Related] [Next] [New Search]